Capital International Inc. CA Purchases 4,742 Shares of Humana Inc. (NYSE:HUM)

Capital International Inc. CA raised its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 35.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,109 shares of the insurance provider's stock after acquiring an additional 4,742 shares during the quarter. Capital International Inc. CA's holdings in Humana were worth $4,594,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter valued at $27,000. Centricity Wealth Management LLC bought a new stake in Humana in the fourth quarter valued at $30,000. LFA Lugano Financial Advisors SA raised its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management bought a new position in shares of Humana during the 4th quarter worth about $33,000. Finally, Atwood & Palmer Inc. increased its position in Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HUM. Truist Financial lifted their target price on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research report on Friday, April 11th. Barclays boosted their target price on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research note on Friday, April 11th. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Mizuho boosted their target price on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $284.90.

Humana Price Performance

HUM traded down $3.91 during trading on Friday, reaching $263.92. The stock had a trading volume of 1,097,937 shares, compared to its average volume of 1,745,453. The business has a 50-day moving average of $266.22 and a 200-day moving average of $270.36. The stock has a market cap of $31.85 billion, a PE ratio of 26.52, a PEG ratio of 2.05 and a beta of 0.62. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. Humana's dividend payout ratio is presently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.